{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:59:20Z","timestamp":1771531160546,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.humpath.2019.08.008","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T11:29:31Z","timestamp":1565954971000},"page":"54-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma"],"prefix":"10.1016","volume":"93","author":[{"given":"Jeff D.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel G.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueliang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2019.08.008_bb0005","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.humpath.2019.08.008_bb0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2019.08.008_bb0020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0025","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V89.3.965","article-title":"Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and\/or mantle cell lymphoma","volume":"89","author":"Uchimaru","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0030","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/j.1460-2075.1994.tb06655.x","article-title":"Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice","volume":"13","author":"Lovec","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.humpath.2019.08.008_bb0035","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2019.08.008_bb0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V98.3.787","article-title":"Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray","volume":"98","author":"Hofmann","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","article-title":"Characterization of 4 mantle cell lymphoma cell lines","volume":"127","author":"Amin","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2019.08.008_bb0050","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Perez-Galan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0055","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cancergencyto.2004.01.006","article-title":"Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519","volume":"153","author":"Rudolph","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.humpath.2019.08.008_bb0060","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1158\/1078-0432.CCR-11-0955","article-title":"ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high\/mcl-1low profile and synergizes with other antineoplastic agents","volume":"17","author":"Touzeau","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2019.08.008_bb0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/path.1254","article-title":"Expression of mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression","volume":"199","author":"Khoury","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0075","doi-asserted-by":"crossref","first-page":"12461","DOI":"10.1073\/pnas.1018941108","article-title":"A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma","volume":"108","author":"Beltran","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2019.08.008_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","article-title":"Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas","volume":"109","author":"Mestre-Escorihuela","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0085","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","article-title":"Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM","volume":"24","author":"Tagawa","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2019.08.008_bb0090","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2013-04-499079","article-title":"Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells","volume":"123","author":"Katz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0095","first-page":"1","article-title":"BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients","author":"Than","year":"2018"},{"key":"10.1016\/j.humpath.2019.08.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078582","article-title":"A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib","volume":"8","author":"Augis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2019.08.008_bb0105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.jid.5700989","article-title":"Bim expression is reduced in human cutaneous melanomas","volume":"128","author":"Dai","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0110","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1158\/1078-0432.CCR-07-5202","article-title":"Prognostic impact of bim, puma, and noxa expression in human colon carcinomas","volume":"14","author":"Sinicrope","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2019.08.008_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.humpath.2018.04.009","article-title":"Bim is an independent prognostic marker in intrahepatic cholangiocarcinoma","volume":"78","author":"Zhang","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0120","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/JTO.0000000000000535","article-title":"The BIM deletion polymorphism and its clinical implication in patients with EGFR-mutant non-small-cell lung cancer treated with EGFR tyrosine kinase inhibitors","volume":"10","author":"Lee","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Ng","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2019.08.008_bb0130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/his.12207","article-title":"Immunohistochemical evaluation of MYC expression in mantle cell lymphoma","volume":"63","author":"Oberley","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2019.08.008_bb0135","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3109\/10428194.2013.815349","article-title":"Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of mantle cell lymphoma international prognostic index and Ki-67 in the era of rituximab: long-term data from the Czech lymphoma project database","volume":"55","author":"Salek","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2019.08.008_bb0145","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0150","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2019.08.008_bb0155","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2015.355","article-title":"SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6","volume":"30","author":"Palomero","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2019.08.008_bb0160","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0165","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1200\/JCO.2009.23.9731","article-title":"Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma","volume":"27","author":"Eve","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0170","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0175","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.humpath.2019.08.008_bb0185","series-title":"in Non-Hodgkin Lymphoma: Pathology, Imaging, and Current Therapy","first-page":"251","article-title":"Treatment Strategies in Mantle Cell Lymphoma","author":"Maddocks","year":"2015"},{"key":"10.1016\/j.humpath.2019.08.008_bb0190","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic lymphoma group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0195","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2019.08.008_bb0200","first-page":"1666-1666","volume":"118","author":"Hillmer","year":"2011","journal-title":"A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia"},{"key":"10.1016\/j.humpath.2019.08.008_bb0205","first-page":"1","article-title":"BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma","author":"Ito","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2019.08.008_bb0210","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2014-03-564534","article-title":"A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0215","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0220","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0225","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0230","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0235","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JGO.2015.000638","article-title":"Impact of the Bim deletion polymorphism on survival among patients with completely resected non-small-cell lung carcinoma","volume":"2","author":"Atsumi","year":"2016","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0240","doi-asserted-by":"crossref","first-page":"16202","DOI":"10.1074\/jbc.275.21.16202","article-title":"Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling","volume":"275","author":"Marchenko","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2019.08.008_bb0245","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1092734","article-title":"Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis","volume":"303","author":"Chipuk","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.humpath.2019.08.008_bb0250","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ncb1123","article-title":"Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex","volume":"6","author":"Leu","year":"2004","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0255","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.onc.1201362","article-title":"p53 expression overcomes p21WAF1\/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells","volume":"15","author":"Kagawa","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2019.08.008_bb0260","article-title":"Ki-67 predicts outcome in advanced stage mantle cell lymphoma patients treated with anti-CD20 immunochemo-therapy: results from randomized trials of the European MCL network and the German low grade lymphoma study group","author":"Determann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5045\/br.2016.51.2.127","article-title":"Prognostic relevance of the Ki-67 proliferation index in patients with mantle cell lymphoma","volume":"51","author":"Jeong","year":"2016","journal-title":"Blood research"},{"key":"10.1016\/j.humpath.2019.08.008_bb0270","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V124.21.2977.2977","article-title":"Tumor cell proliferation (Ki-67 index) overcomes cytology and growth pattern as prognostic factor in mantle-cell lymphoma \u2013 results from randomized trials of the European MCL network","volume":"124","author":"Hoster","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0275","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0280","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The mantle cell lymphoma international prognostic index (MIPI) is superior to the international prognostic index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0285","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.V89.4.1421","article-title":"Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones","volume":"89","author":"Ott","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0290","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/S0046-8177(03)00412-X","article-title":"Cytogenetic findings in blastoid mantle cell lymphoma","volume":"34","author":"Khoury","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0295","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants","volume":"93","author":"Bea","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0300","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0305","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.MP.0000037310.82136.99","article-title":"Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features","volume":"15","author":"Hao","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0310","doi-asserted-by":"crossref","first-page":"22473","DOI":"10.1074\/jbc.M109.081042","article-title":"Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim","volume":"285","author":"Han","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2019.08.008_bb0315","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1073\/pnas.0401471101","article-title":"Bim is a suppressor of Myc-induced mouse B cell leukemia","volume":"101","author":"Egle","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2019.08.008_bb0320","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/sj.leu.2401599","article-title":"C-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas","volume":"13","author":"Hernandez","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2019.08.008_bb0325","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/sonc.2003.50024","article-title":"Rituximab plus chemotherapy in follicular and mantle cell lymphomas","volume":"30","author":"Hiddemann","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.humpath.2019.08.008_bb0330","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1(\u2212) mantle cell lymphoma","volume":"121","author":"Salaverria","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.08.008_bb0335","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","article-title":"The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective","volume":"175","author":"Satterthwaite","year":"2000","journal-title":"Immunol Rev"},{"key":"10.1016\/j.humpath.2019.08.008_bb0340","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2019.08.008_bb0345","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2019.08.008_bb0350","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2019.08.008_bb0355","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2019.08.008_bb0360","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817719301418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817719301418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:36:09Z","timestamp":1758645369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817719301418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":72,"alternative-id":["S0046817719301418"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2019.08.008","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2019.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}